Product Details
SEMAGLUTIDE 1.7MG/0.75 PEN ML WEGOVY®
Manufacturer: NOVO NORDISK
MFG#: 00169-4517-01
NDC: 00169-4517-01
PID: 641009
1/EA
$ *.**
In StockEA
$ *.**
In StockAdditional Information
| Product Name | Wegovy® (semaglutide) injection 1.7 mg |
| Active Ingredient | Semaglutide (base form), a GLP-1 receptor agonist |
| Concentration | 1.7 mg per 0.75 mL dose (2.27 mg/mL) |
| Regulatory Status | FDA-approved drug; listed under the FDA’s Orange Book. |
| Intended Use | For chronic weight management in adults with obesity or overweight with at least one weight-related condition, and to reduce the risk of major cardiovascular events in adults with known heart disease and obesity or overweight. |
| Dosage Form | Pre-filled, single-patient-use pen injector. |
Description
Wegovy® (semaglutide) injection is an FDA-approved prescription medication for long-term weight management. The 1.7 mg dose is typically reached after a 16-20 week dose-escalation schedule (starting from 0.25 mg) to improve gastrointestinal tolerability. It is a therapeutic maintenance dose, and patients may continue on this dose or escalate to the 2.4 mg dose based on clinical response, tolerability, and the advice of their prescriber only.
It is a therapeutic equivalent to other Wegovy® pens of the same strength and should not be confused with compounded semaglutide products. Dispensed only pursuant to a valid prescription. For subcutaneous injection once weekly in the abdomen, thigh, or upper arm. Dosing must be determined and supervised by a qualified healthcare professional.
Important Safety Information
This is an FDA-approved drug with an established safety profile. However, it carries a BOXED WARNING about the risk of thyroid C-cell tumors in rodents; the human relevance is unknown. Wegovy® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) . Other serious side effects may include pancreatitis, gallbladder problems, hypoglycemia, and kidney injury . Patients should be counseled on the full safety information.
Frequently Asked Questions (FAQs)
The cost of SEMAGLUTIDE 1.7MG/0.75 PEN ML WEGOVY® is $$0.00
SEMAGLUTIDE 1.7MG/0.75 PEN ML WEGOVY® is manufactured by NOVO NORDISK.
You can purchase SEMAGLUTIDE 1.7MG/0.75 PEN ML WEGOVY® on our website at https://supplies.pipelinemedical.com/product/detail/semaglutide-1-7mg-0-75-pen-ml-wegovy-641009